There are 383 resources available
190P - COVID-19 pandemic impact on lung cancer patient’s performance status and access to treatment: A comparative study pre and during COVID-19 era
Presenter: Rute Fernandes
Session: Poster Display session
191P - Lung cancer care in Europe during COVID-19: Findings from a global survey of patient experience
Presenter: Jackie Fenemore
Session: Poster Display session
192P - Randomized, phase II, placebo-controlled trial of nintedanib for the treatment of radiation pneumonitis
Presenter: Zachary Moore
Session: Poster Display session
193P - Safety and efficacy of immmunotherapy rechallenge following a previous immune-induced interstial lung disease
Presenter: Célia Joseph
Session: Poster Display session
9P - Final results from TAIL: Updated long-term safety and efficacy of atezolizumab (atezo) in a diverse population of patients (pts) with previously treated advanced NSCLC
Presenter: Andrea Ardizzoni
Session: Poster Display session
10P - Treatment-free survival (TFS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with 1L nivolumab plus ipilimumab (NIVO+IPI) or platinum doublet chemotherapy (PDC) in CheckMate (CM) 227
Presenter: Solange Peters
Session: Poster Display session
11P - Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in 2nd line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts
Presenter: Matthew Krebs
Session: Poster Display session
12P - A phase II study of atezolizumab in combination with bevacizumab, carboplatin or cisplatin, and pemetrexed for EGFR-mutant metastatic NSCLC patients after failure of EGFR TKIs
Presenter: Shang-gin Wu
Session: Poster Display session
13P - Durvalumab + chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis
Presenter: Byoung Chul Cho
Session: Poster Display session
14P - Flat-dose nivolumab (NIVO) as second-line (2L) treatment (tx) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC): CheckMate 870 long-term results
Presenter: Shun Lu
Session: Poster Display session